[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371144-105":59,"doc-detail-371144-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","heterogeneity-of-urinary-system-tumors-novel-avenues-for-targeted-therapy-and-precision-medicine","Heterogeneity of Urinary System Tumors - Novel Avenues for Targeted Therapy and Precision Medicine","","Urinary system tumors, including bladder, kidney, and prostate cancers, create a major global health burden and show extensive molecular and genetic heterogeneity. The review analyzes how this heterogeneity shapes treatment effectiveness and why conventional approaches often fall short. It maps targeted therapy strategies to precision medicine, emphasizing target discovery through multi-omics data, the selection of specific molecular or genetic aberrations, and the customization of treatment for individual patients while addressing resistance and safety limitations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/heterogeneity-of-urinary-system-tumors-novel-avenues-for-targeted-therapy-and-precision-medicine/371144/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/heterogeneity-of-urinary-system-tumors-novel-avenues-for-targeted-therapy-and-precision-medicine/371144.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main clinical problem addressed in the review?","Question",{"text":112,"@type":113},"Urinary system tumors impose a substantial health burden and show significant molecular and genetic heterogeneity, which limits conventional treatment effectiveness.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does precision medicine relate to targeted therapy in this review?",{"text":117,"@type":113},"Precision medicine tailors treatments to individual patients using genetic, molecular, and clinical profiles, while targeted therapy develops drugs based on specific molecular or genetic aberrations identified as cancer-driving targets.",{"name":119,"@type":110,"acceptedAnswer":120},"What factors limit targeted therapy for urinary system tumors?",{"text":121,"@type":113},"The review highlights the emergence of resistance mechanisms and the potential for adverse effects as key limitations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371144,1791160120,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Journal of Advanced Research 85 (2026) 837–852  \nContents lists available at ScienceDirect  \nJournal of Advanced Research  \njournal [homepage: www. elsevier. com/locate/jare](homepage: www. elsevier. com/locate/jare)  \nHeterogeneity of urinary system tumors: novel avenues for targeted therapy and precision medicine  \nHao Chen a, 1, Yang Wengb, 1, Donghan Zheng c, 1, Tian Li e,⁎, Nan Xud,⁎, Longdan Kangf,⁎, Liang Feng a,⁎  \na Department of Breast Surgery, The First Hospital of China Medical University, PR China  \nb Department of Digestive Endoscopy, The Fourth Afﬁliated Hospital of China Medical University, PR China c Department of Cardiology, The Fourth Afﬁliated Hospital of China Medical University, PR China  \nd Department of Plastic Surgery, the Afﬁliated Hospital of China Medical University, Shenyang 110001 Liaoning, PR China  \ne Tianjin Key Laboratory of Acute Abdomen Disease-Associated Organ Injury and ITCWM Repair, Institute of Integrative Medicine of Acute Abdominal Diseases, Tianjin Nankai Hospital, Tianjin Medical University, 8 Changjiang Avenue, Tianjin 300100, PR China  \nf Department of Ophthalmology, The First Hospital of China Medical University, Shenyang 110001, PR China  \nh i g h l i g h t s  \n• Precision medicine has potential for the treatment of urinary system tumors.  \n• Urinary system tumors are characterized by molecular and genetic heterogeneity.  \n• Targeted therapy represents a more precise and individualized therapeutic strategy.  \n• EGFR and VEGF are prominent molecular targets for the treatment of urinary system tumors.  \ng r a p h i c a l a b s t r a c t  \nThe heterogeneity of urinary system tumors and its impact on precision medicine. The diagram highlights genetic mutations, molecular phenotype differences, and immune microenvironment variability in bladder cancer, kidney cancer, and prostate cancer. These ﬁndings emphasize how these heterogeneities affect treatment responses and the role of genomic proﬁling in targeted therapies for personalized treatment.  \na r t i c l e i n f o  \nArticle history:  \nReceived 22 April 2025  \nRevised 17 September 2025 Accepted 17 October 2025 Available online 22 October 2025  \na b s t r a c t  \nBackground: Urinary system tumors, including bladder, kidney, and prostate cancers, impose a substantial health burden worldwide and exhibit signiﬁcant molecular and genetic heterogeneity.  \nAim: of Review: This review delves into the intricate landscape of targeted therapy for urinary system tumors and its pivotal role in advancing precision medicine.  \nAbbreviations: RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; NEPC, neuroendocrine prostate cancer; DRE, digital rectal examination; HIFs, hypoxiainducible factors; VEGF, vascular endothelial growth factor; FH, fumarate hydratase; AR, androgen receptor; EGFR, epidermal growth factor receptor; FGFR, ﬁbroblast growth factor receptor; ADT, androgen deprivation therapy; PD-1/PD-L1, Programmed Death-1/Programmed Death-Ligand 1; nmCRPC, non-metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; NGS, next-generation sequencing; PSA, prostatespeciﬁc antigen; AI, artiﬁcial intelligence; ML, machine learning; ctDNA, circulating tumor DNA; TKIs, tyrosine kinase inhibitors.  \n⁎ Corresponding authors at: Department of Breast surgery, The First Hospital of China Medical University, 155 Nanjing North St, Shenyang 110000, PR China. E-mail addresses: [fmmult@foxmail.com](fmmult@foxmail.com) (T. Li), [20071099@cmu.edu.cn](20071099@cmu.edu.cn) (N. Xu), [419151779@qq.com](419151779@qq.com) (L. Kang), [fengliang@cmu.edu.cn](fengliang@cmu.edu.cn) (L. Feng).  \n1 Equal contribution.  \n[https://doi.org/10.1016/j.jare.2025.10.026](https://doi.org/10.1016/j.jare.2025.10.026)  \n2090-1232/© 2025 The Authors. Published by Elsevier B.V. on behalf of Cairo University.  \nThis is an open access article under the CC BY-NC-ND license (","cbCaiuR0Bcrusd93","https://ap.wps.com/l/cbCaiuR0Bcrusd93","pdf",2086005,16,"English","# Highlights\n## Precision medicine and heterogeneity in urinary system tumors\n## Targeted therapy and molecular targets\n# Graphical abstract\n## Impact of genetic mutations and immune microenvironment variability\n# Article information\n## Article history\n## Abstract and aim\n# Key scientific concepts of review\n## Precision medicine vs conventional therapy\n## Biomarkers, genomics, and personalized treatment\n## Limitations: resistance and adverse effects\n# Conclusion","[{\"question\":\"What is the main clinical problem addressed in the review?\",\"answer\":\"Urinary system tumors impose a substantial health burden and show significant molecular and genetic heterogeneity, which limits conventional treatment effectiveness.\"},{\"question\":\"How does precision medicine relate to targeted therapy in this review?\",\"answer\":\"Precision medicine tailors treatments to individual patients using genetic, molecular, and clinical profiles, while targeted therapy develops drugs based on specific molecular or genetic aberrations identified as cancer-driving targets.\"},{\"question\":\"What factors limit targeted therapy for urinary system tumors?\",\"answer\":\"The review highlights the emergence of resistance mechanisms and the potential for adverse effects as key limitations.\"}]","Heterogeneity of Urinary System Tumors - Novel Avenues for Targeted Therapy and Precision Medicine | PDF",1790191346,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5072e993c1d8de6a74567c6747e9c5c6.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/106acfab170caa4cb5213c18b0aeadb0.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc94ba393396eb3fca271ed145d61ac4.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44f965028d025c9f6762911a4d6bd872.webp",980,1306]